nach oben

Erschienen in:

01.12.2023 | Review

Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

verfasst von: Deniz Can Guven, Enes Erul, Yunus Kaygusuz, Baran Akagunduz, Saadettin Kilickap, Raffaele De Luca, Alessandro Rizzo

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Immune checkpoint inhibitors (ICIs) are related to various immune-related adverse events (irAEs). However, the knowledge is limited with rare irAEs like hearing loss. Therefore, we evaluated the characteristics, presentation, and treatment of ICI-related hearing loss by reviewing the individual patient data from the previous studies.

Methods

We conducted a systematic search of the Web of Science, PubMed, and Embase databases for studies published until 17 November 2022. The selected MeSH search terms were “hearing loss” OR “hearing impairment” OR “ototoxicity” OR “vestibular toxicity” OR “audiovestibular toxicity” AND “immune checkpoint inhibitor” OR “immunotherapy.”

Results

A total of 38 patients were included. Melanoma was the most frequent diagnosis (73.7%). The median time from ICI initiation to hearing loss development was 3 months. The hearing impairment was secondary to bilateral sensorineural hearing loss (SNHL) in 24 (68.6%) patients, and at least one other irAE accompanied the hearing loss in 24 patients. Hearing loss significantly improved in 45.7% of the patients. The overall response rate and disease control rate were 67.6% and 85.3%, respectively.

Conclusion

We observed that most cases of ICI-related hearing loss were reversible, observed in patients with melanoma, accompanied by other irAEs, and associated with a high response rate to ICIs. With the expanded use of ICIs in the earlier treatment lines and adjuvant settings, the number of survivors with ICI-related hearing loss is expected to increase. Further research is needed to define the true prevalence of ICI-related hearing loss, optimal diagnosis, and management.

Postow MA, Sidlow R, Hellmann MD (2018) Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378(2):158–168PubMed

Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95PubMedPubMedCentral

Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580PubMed

Lemasson J, Cuzzubbo S, Doucet L et al (2019) Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. Eur J Cancer 117:116–118PubMed

Nader ME, Myers JN, Gidley PW (2017) Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis. J Immunother Cancer 5:24PubMedPubMedCentral

Zibelman M, Pollak N, Olszanski AJ (2016) Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer 4:8PubMedPubMedCentral

Page JC, Gidley PW, Nader ME (2022) Audiovestibular Toxicity Secondary to Immunotherapy: Case Series and Literature Review. J Immunother Precis Oncol 5(1):2–6PubMedPubMedCentral

Rajapakse A, O'Leary C, Gundelach R et al (2020) Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxf Med Case Reports 2020(9):omaa077

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71PubMedPubMedCentral

10.

Boutros C, Peres E, Routier E et al (2022) Severe ototoxicity associated with immune checkpoint inhibitors (ICI) in advanced melanoma. Eur J Cancer 173:204–206PubMed

11.

Vogrig A, Muñiz-Castrillo S, Joubert B et al (2021) Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology 96(6):e866–e875PubMed

12.

Tampio AJF, Dhanireddy S, Sivapiragasam A et al (2021) Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma. Ear Nose Throat J 100(3_suppl):286s–291sPubMed

13.

Godse R, McGettigan S, Schuchter LM et al (2021) Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy. Clin Exp Dermatol 46(6):1111–1112PubMed

14.

Rosner S, Agrawal Y, Sun DQ et al (2020) Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. J Immunother Cancer 8(2):e001675PubMedPubMedCentral

15.

Gambichler T, Seifert C, Lehmann M et al (2020) Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 12(7):439–444PubMed

16.

Fujimura T, Kambayashi Y, Tanita K et al (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol 45(6):735–737PubMed

17.

Choi JS, Chen M, McQuade JL et al (2020) Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head Neck 42(11):E35-e42PubMed

18.

Koch EAT, Nickel FT, Heinzerling L et al (2021) Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. J Immunother 44(3):114–117PubMed

19.

Voskens C, Cavallaro A, Erdmann M et al (2012) Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30(33):e356-357PubMed

20.

Hanna KS (2016) A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Pharmacotherapy 36(11):e183–e188PubMed

21.

De Groot M, Compter A, De Langen AJ et al (2020) Susac’s syndrome as an immune-related adverse event after pembrolizumab: a case report. J Neurol 267(1):282–284PubMed

22.

Conrady CD, Larochelle M, Pecen P et al (2018) Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol 256(1):187–191PubMed

23.

Karzai F, VanderWeele D, Madan RA et al (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 6(1):141PubMedPubMedCentral

24.

Dolaghan MJ, Oladipo B, Cooke CA et al (2019) Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland. Eye (Lond) 33(10):1670–1672PubMed

25.

Stürmer SH, Lechner A, Berking C (2021) Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors. J Immunother 44(5):193–197PubMed

26.

Ma W, Xue R, Zhu Z et al (2023) Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 12(1):10PubMedPubMedCentral

27.

Rajput K, Edwards L, Brock P et al (2020) Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer. Int J Pediatr Otorhinolaryngol 138:110401PubMed

28.

Sanchez VA, Shuey MM, PCD Jr (2003) Patient-reported functional impairment due to hearing loss and tinnitus after cisplatin-based chemotherapy. J Clin Oncol 41(12):2211–2226

29.

Chern A, Golub JS (2019) Age-related Hearing Loss and Dementia. Alzheimer Dis Assoc Disord 33(3):285–290PubMedPubMedCentral

30.

Steel KP, Barkway C (1989) Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear. Development 107(3):453–463PubMed

31.

Mujica-Mota MA, Schermbrucker J, Daniel SJ (2015) Eye color as a risk factor for acquired sensorineural hearing loss: A review. Hear Res 320:1–10PubMed

32.

Locher H, de Groot JC, van Iperen L et al (2015) Development of the stria vascularis and potassium regulation in the human fetal cochlea: Insights into hereditary sensorineural hearing loss. Dev Neurobiol 75(11):1219–1240PubMedPubMedCentral

33.

Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150PubMedPubMedCentral

34.

Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 151(11):1206–1212PubMedPubMedCentral

35.

Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773–781PubMed

36.

Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 22(4):886–894PubMed

37.

Suresh K, Naidoo J (2020) Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer. Clin Lung Cancer 21(3):e169–e170PubMed

38.

Bai X, Hu J, Betof Warner A et al (2021) Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy. Clin Cancer Res 27(21):5993–6000PubMedPubMedCentral

39.

Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706–3714PubMed

40.

Dall’Olio FG, Rizzo A, Mollica V et al (2021) Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 13(3):257–270PubMed

41.

Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073–4126PubMed

42.

Sialakis C, Iliadis C, Frantzana A et al (2022) Intratympanic Versus Systemic Steroid Therapy for Idiopathic Sudden Hearing Loss: A Systematic Review and Meta-Analysis. Cureus 14(3):e22887PubMedPubMedCentral

43.

Dallan I, Fortunato S, Casani AP et al (2014) Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiological and quality of life evaluation. J Laryngol Otol 128(8):669–673PubMed

44.

Kakehata S, Sasaki A, Oji K et al (2006) Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes. Otol Neurotol 27(5):604–608PubMed

45.

Salvi R, Ding D, Jiang H et al (2018) Hidden Age-Related Hearing Loss and Hearing Disorders: Current Knowledge and Future Directions. Hearing Balance Commun 16(2):74–82PubMedPubMedCentral

46.

Xing P, Zhang F, Wang G et al (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 7(1):341PubMedPubMedCentral

47.

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N Engl J Med 378(22):2078–2092PubMed

48.

Colombo N, Dubot C, Lorusso D et al (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 385(20):1856–1867PubMed

49.

Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 394(10212):1915–1928

Titel: Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
verfasst von: Deniz Can Guven
Enes Erul
Yunus Kaygusuz
Baran Akagunduz
Saadettin Kilickap
Raffaele De Luca
Alessandro Rizzo
Publikationsdatum: 01.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 12/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-08083-w

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Leisure-time physical activity, daily sitting time, and mortality among US skin cancer survivors

Incidence, severity, and temporal development of oral complications in pediatric allogeneic hematopoietic stem cell transplant patients – a multicenter study

Vaginal morbidity, sexual functioning, and health-related quality of life in cervical cancer survivors: a cross-sectional multicenter study (VAMOS)

Is there a need for change in cancer survivorship care? A qualitative exploration of survivor experiences and needs at the Sydney Cancer Survivorship Centre Clinic

Cancer-related fatigue self-management: a MASCC-endorsed practice framework for healthcare professionals to optimally support cancer survivors